Business Context and Reporting Period
The filing identifies the registrant as Galecto, Inc. (Nasdaq: GLTO), not Damora Therapeutics, Inc. It is an unaudited Form 10-Q for the quarter and nine months ended September 30, 2021, filed November 4, 2021. Galecto is a clinical-stage biotechnology company developing small-molecule therapies targeting fibrosis and cancer, with no approved products or product revenue.
- Lead program: GB0139, an inhaled galectin-3 inhibitor in the Phase 2b GALACTIC-1 trial for idiopathic pulmonary fibrosis; topline results were expected by mid-2023.
- GB2064 entered a Phase 2a myelofibrosis trial in the third quarter of 2021; interim results were expected in the first half of 2022 and topline results by year-end 2022.
- GB1211 entered a Phase 1b/2a liver-cirrhosis trial in the third quarter of 2021. A planned NSCLC combination trial with Roche’s Tecentriq was expected to begin in the first half of 2022.
Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $9.7 million | $28.4 million |
| General and administrative expense | $3.2 million | $10.4 million |
| Total operating expenses | $12.9 million | $38.8 million |
| Loss from operations | $(12.9) million | $(38.8) million |
| Net loss | $(12.7) million | $(38.3) million |
| Net loss per common share | $(0.50) | $(1.52) |
| Net cash used in operating activities | Not provided for quarter | $(34.5) million |
There is no meaningful revenue or operating margin because the company remains pre-commercial and loss-making. The company reported an accumulated deficit of $142.7 million at September 30, 2021.
- Cash and cash equivalents: $66.2 million.
- Marketable securities: $61.5 million, consisting of $36.0 million current and $25.5 million long-term securities.
- Total cash, cash equivalents and marketable securities: $127.6 million.
- Total current assets: $107.0 million; current liabilities: $5.7 million.
- Total liabilities: $6.3 million, primarily current operating obligations and lease liabilities; the filing does not identify material debt financing.
- Operating lease liabilities totaled $0.9 million, with $1.0 million of undiscounted future lease payments.
- Stock-based compensation expense was $1.2 million for the quarter and $3.2 million for the nine-month period.
Material Changes Versus the Prior Comparable Period
- Quarterly R&D expense increased 27.4% to $9.7 million, driven primarily by higher GALACTIC-1 and other clinical-trial costs and increased personnel expense.
- Nine-month R&D expense increased 68.1% to $28.4 million, reflecting a $7.5 million increase in clinical-trial-related activities, higher chemistry, manufacturing and controls costs, and increased headcount.
- Quarterly G&A expense increased 26.9% to $3.2 million; nine-month G&A expense increased 90.2% to $10.4 million, primarily due to insurance, personnel, stock-based compensation and consultant costs.
- Quarterly net loss increased from $11.7 million to $12.7 million; nine-month net loss increased from $23.3 million to $38.3 million.
- Operating cash burn increased from $23.7 million to $34.5 million for the nine-month period.
- Investing activities used $62.5 million in the 2021 nine-month period as the company purchased marketable securities; there were no comparable investing activities in 2020.
- There was no financing cash inflow in 2021, compared with $95.6 million in 2020 from preferred-stock issuances.
- Cash, cash equivalents and restricted cash declined from $85.6 million at September 30, 2020 to $66.2 million at September 30, 2021, while the company shifted substantial funds into marketable securities.
Guidance, Outlook, Risks and Unusual Items
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund operating and capital requirements into the second half of 2024, subject to assumptions that may prove inaccurate.
- The company expects continuing losses and increasing R&D, G&A and capital expenditures. Additional financing will be required to fund operations beyond the projected runway.
- COVID-19 delayed patient recruitment in GALACTIC-1 and delayed initiation of other trials. The company added investigator sites and expanded recruiting countries but warned that further disruption could delay enrollment and increase costs.
- Clinical, regulatory, manufacturing, intellectual-property, competitive, personnel and commercialization risks remain substantial. The company may never obtain regulatory approval or generate significant product revenue.
- The company reported no material changes to previously disclosed commitments and contingencies and no material legal proceedings.
- Management concluded that disclosure controls and procedures were not effective as of September 30, 2021 because of material weaknesses in internal control over financial reporting previously reported in the 2020 Form 10-K.
- The company had not used the $86.3 million of net IPO proceeds as of September 30, 2021; unused proceeds were held in money-market accounts and marketable debt securities.
- The filing states that no subsequent events requiring disclosure occurred through issuance of the financial statements.
Investor Verification Items
- Verify the issuer identity: the supplied metadata names Damora Therapeutics, while the filing itself names Galecto, Inc., ticker GLTO.
- Track GALACTIC-1 enrollment, timing and topline results, including the continuing effects of COVID-19 on screening and recruitment.
- Assess clinical data and execution for GB2064 and GB1211, including the planned GB1211/Tecentriq collaboration trial.
- Reconcile the stated cash runway with quarterly cash burn, clinical-trial expansion and potential financing needs.
- Monitor dilution risk from future equity offerings and the 3.9 million outstanding stock options as of September 30, 2021.
- Review remediation of the material weaknesses in internal control over financial reporting.
- Confirm regulatory milestones, manufacturing readiness, intellectual-property protection and the absence of product revenue until approval and commercialization.